PLEOPHARMA, INC. filed a Form D with the Securities and Exchange Commission on 2025-08-08.
PLEOPHARMA, INC. filed a Form D notice of an exempt securities offering with the SEC on August 8, 2025. PLEOPHARMA, INC. was formerly named Pleopharma L.L.C. The filing reports $6.15M sold. Its industry group is Pharmaceuticals. It names Ginger Constantine (Executive Officer, Director), Jay Constantine (Executive Officer, Director), Robert Finizio (Director) (SEC Form D, August 8, 2025).
In its own words: “PleoPharma pharmaceutical company homepage, management team, product offering, contact us.” (pleopharma.com, checked October 31, 2026)
Is this your company?
Sell to companies like PLEOPHARMA, INC? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
New Form D on file · 2025-08-08 · the record
Pitching, partnering or investing alongside them? See who really runs and owns PLEOPHARMA, INC.
Free to see. No signup.
More on the people and the money behind PLEOPHARMA, INC., from the filings we hold.
Castle Hill Capital Partners, Inc received sales compensation on this raise and on 10 other raises we hold, nearest in date first:
Supervision Partners LLC received sales compensation on this raise and on 3 other raises we hold, nearest in date first:
Pharmaceuticals raises by companies based in Pennsylvania, filed within 90 days of this one, largest first.
Get an email when PLEOPHARMA, INC. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
We'll show it in your MentionFox inbox when PLEOPHARMA, INC. raises, hires or launches. No email unless you switch it on.
Watch PLEOPHARMA, INC. →Get the full cited report on PLEOPHARMA, INC.
What the filing shows about PLEOPHARMA, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on PLEOPHARMA, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
The filing gives PLEOPHARMA, INC.'s address as 518 Kimberton Rd., Suite 339, Phoenixville, PA 19460.
Saved here on this device in the meantime, so nothing is lost either way.
Full funding history for PLEOPHARMA, INC. →
This is the company's own disclosure. A payment disclosed on a Form D is a disclosed use of proceeds, not a finding of wrongdoing.
PLEOPHARMA, INC. is a registered filer with the SEC (CIK 1801323) and has filed since 2025-08-08. 2 filings are on record, the latest on 2026-08-10.
A filing shows the company exists and what it reports about itself. It is not an audit or a rating.
PLEOPHARMA, INC.'s Form D of 2025-08-08 names Ginger Constantine, Jay Constantine, Robert Finizio and 7 more as its officers, directors or promoters.
Its new offerings report $11.65M sold across 2 offerings, as its own filings state.
Each marker is one filing. The larger marker is the filing this page is about.
Trailing twelve months. 155 filings in Pharmaceuticals, totalled by week.
Checked away from the filing. What is below does not come from the record on sec.gov.
PleoPharma pharmaceutical company homepage, management team, product offering, contact us.
The title and description the site itself served, answering 200, after redirecting from https://pleopharma.com. Not a cached copy and not the company's directory entry — what was live when we asked.
Ginger Constantine is named as Executive Officer and Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Jay Constantine is named as Executive Officer and Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Robert Finizio is named as Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Bisaro Paul is named as Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Thompson Tommy is named as Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Sarah Hassan is named as Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Brij Sharma is named as Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Daniel Cartwright is named as Executive Officer on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Thomas Poche is named as Executive Officer on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
Timothy McInerney is named as Director on the Form D that PLEOPHARMA, INC. filed with the SEC on 8 August 2025, one of 10 people that filing names.
10 people named on the filing — 4 holding an executive role and 6 as directors only.
Named as of the 2025-08-08 filing. Titles and locations are exactly as the filing states — not independently confirmed elsewhere.
No investor is drawn from a Form D — the form states how many invested and never who.
What the filing shows about PLEOPHARMA, INC.
Only in the Full Report: Who Runs It, And How To Reach Them · Warning Bells · Who Pays Them, And Who They Are Up Against.
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on PLEOPHARMA, INC.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on PLEOPHARMA, INC. covers
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
You land back on this company when you are in.
Not ready to upgrade? Keep this one in view instead.
Watchlist PLEOPHARMA, INC.You get an alert in MentionFox the next time this company shows up.
If you're behind PLEOPHARMA, INC.: the weeks after a raise are watched the same way — by other investors sizing you up, and by founders checking who just got funded. FoxPlug turns your commits, deploys, and releases into that story automatically. GetFoxChat puts a guide on your own site so the people this filing just sent you don't leave after one page.
Sourced from the filing index on sec.gov, and from the company's own site, read directly on 2026-11-01 (pleopharma.com).
Each opens in a new tab, filled in for PLEOPHARMA, INC.. With no account yet, you sign up free and land on the result.
Share your raise. This card is drawn from the company's own Form D filing, and sharing needs no account.
https://mentionfox.com/funding/pleopharma-inc-form-d-25000001